Pharmaceutical Technology17 天
D2C7-IT by Istari Oncology for Glioblastoma Multiforme (GBM): Likelihood of Approval
D2C7-IT is under clinical development by Istari Oncology and currently in Phase II for Glioblastoma Multiforme (GBM).